CISPLATIN PLUS VP16-213 IN REFRACTORY OVARIAN-CARCINOMA

被引：11

作者：

LELE, SB

PIVER, MS

MALFETANO, J

机构：

[1] NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT CLIN GYNECOL ONCOL, 666 ELM ST, BUFFALO, NY 14263 USA

[2] ALBANY MED SCH, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, ALBANY, NY USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1987年 / 10卷 / 01期

关键词：

D O I：

10.1097/00000421-198702000-00004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-five patients with FIGO stage III and IV ovarian carcinoma were treated with cisplatin plus VP16-213 chemotherapy as the second, third, or fourth line of therapy. There were two (8%) partial responses, 18 with stable disease and five with progression of disease. Neurotoxicity was observed in all patients, with two patients developing severe paresthesias and difficulty in walking.

引用

页码：21 / 22

页数：2

共 7 条

[1]

NISSEN NI, 1980, CANCER-AM CANCER SOC, V45, P232, DOI 10.1002/1097-0142(19800115)45:2<232::AID-CNCR2820450206>3.0.CO

[2]

2-F

[3]

SCHABEL FM, 1979, CANCER TREAT REP, V63, P1459

[4]

SLAYTON RE, 1979, CANCER TREAT REP, V63, P2089